APA (7th ed.) Citation

(2020). Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge.

Chicago Style (17th ed.) Citation

Early Administration of Interleukin-6 Inhibitors for Patients with Severe COVID-19 Disease Is Associated with Decreased Intubation, Reduced Mortality, and Increased Discharge. 2020.

MLA (8th ed.) Citation

Early Administration of Interleukin-6 Inhibitors for Patients with Severe COVID-19 Disease Is Associated with Decreased Intubation, Reduced Mortality, and Increased Discharge. 2020.